What Is Malignant Hematology?

Yao Ergu, male, born in January 1931, Changshu, Jiangsu. He graduated from the Medical Department of Shanghai Medical College of Fudan University in 1953, and graduated as a postgraduate in hematology at the Medical College of Suzhou University in 1968. He is currently a professor and chief physician of the Department of Hematology of the Second Hospital of Hebei Medical University. He has served as the second, third, and fourth standing members of the Chinese Medical Association's Blood Branch, the chairman of the Hebei Medical Association's Blood Branch, the chairman of the Internal Medicine Branch, and the editorial board of 8 journals including the Chinese Journal of Hematology and Leukemia · Lymphoma. He has edited 8 monographs including "Diagnosis and Treatment of Special Hematological Diseases", "Newly Edited Leukemia Chemotherapy", and edited "Deng Jiadong's Clinical Hematology" and "Diagnosis and Efficacy Standards for Hematological Diseases", and published nearly 180 Chinese and English papers. . He has successively won three third prizes and one fourth prize in Hebei Province's scientific and technological progress award, and more than ten second prizes in scientific and technological progress in the provincial health department. Has been rated as the province's outstanding contributions to young and middle-aged scientific and technological talents, the province's advanced health scientific research individuals, provincial excellent experts and other titles. Enjoy special government allowances.

Diagnosis and treatment of malignant hematological diseases

The clinical classification and treatment of malignant hematological diseases are relatively complicated. Hematology experts who have been working in the clinical field for a long time have been specially prepared this book. Introduced according to the latest classification of hematopoietic system and lymphoid tissue tumors of the World Health Organization (WHO), supplemented by multidrug resistance mechanisms and their reversal, application of flow cytometry in hematological diseases, vascular growth and hematological diseases, leukemia Targeted therapies, toxic response classification of WHO chemotherapy drugs, crisis of hematological malignancies, and thalidomide (response to stop) treatment of malignant hematological diseases. The book consists of 18 chapters. It describes the clinical manifestations, hematological changes, immune phenotypes, diagnosis and differential diagnosis, and treatment of various malignant hematological diseases. It also focuses on chemotherapy and efficacy standards. This book is closely combined with clinical reality, and reflects the current level of classification and diagnosis and treatment of malignant hematological diseases at home and abroad. The content is novel and practical. It is an essential reference book for clinicians and graduate students who work in blood diseases and related disciplines.

Book title

Diagnosis and treatment of malignant hematological diseases

Publishing house

People's Military Medical Publishing House

Fixed price

35.00

Author

Yao Ergu

ISBN

7801579909

Brand

People's Military Medical Publishing House

Yao Ergu, male, born in January 1931, Changshu, Jiangsu. He graduated from the Medical Department of Shanghai Medical College of Fudan University in 1953, and graduated as a postgraduate in hematology at the Medical College of Suzhou University in 1968. He is currently a professor and chief physician of the Department of Hematology of the Second Hospital of Hebei Medical University. He has served as the second, third, and fourth standing members of the Chinese Medical Association's Blood Branch, the chairman of the Hebei Medical Association's Blood Branch, the chairman of the Internal Medicine Branch, and the editorial board of 8 journals such as the Chinese Journal of Hematology and Leukemia · Lymphoma. He has edited 8 monographs including "Diagnosis and Treatment of Special Hematological Diseases", "Newly Edited Leukemia Chemotherapy", and edited "Deng Jiadong's Clinical Hematology" and "Diagnosis and Efficacy Standards for Hematological Diseases". . He has successively won three third prizes and one fourth prize in Hebei Province's scientific and technological progress award, and more than ten second prizes in scientific and technological progress in the provincial health department. Has been rated as the province's outstanding contributions to young and middle-aged scientific and technological talents, the province's advanced health scientific research individuals, provincial excellent experts and other titles. Enjoy special government allowances.

Chapter 1 Myelodysplastic Syndrome I. Classification II. Problems to be Noted in Diagnosing MDS III. Special Clinical Features of MDS IV. Pediatric MDS
V. Integral system for predicting the conversion of MDS to leukemia 6. Treatment VII. Curative effect standards Chapter 2 Chronic bone marrow proliferative disease 1. Chronic myelogenous leukemia 2. Chronic neutrophil leukemia 3. Chronic eosinophilic leukemia and high Eosinophil Syndrome IV. Erythrocytosis V. Chronic Idiopathic Myelofibrosis 6. Idiopathic Thrombocytosis 7. Chronic Myeloproliferative Diseases Cannot Be Classified Chapter 3. Myelodysplastic Disorders / Myeloproliferative Diseases Chapter Chapter 4 Acute Myeloid Leukemia Chapter 5 Acute Lymphoblastic Leukemia Chapter 6 Mature B Cell Tumors Chapter 7 Mature T and NK Cell Tumors Chapter 8 Hodgkin's Lymphoma Chapter 9 Immune Deficiency-Associated Lymphoproliferative Diseases Chapter 10 Chapter Tissue Cell and Dendritic Cell Tumors Chapter 11 Mast Cell Hyperplasia Chapter 12 WHO Classification of Toxic Adverse Reactions to Chemotherapy Drugs Chapter 13 Malignant Hematological Crisis Chapter 14 Multidrug Resistance and Reversal of Acute Leukemia Chapter 15 Chapter Angiogenesis and Malignant Hematological Diseases Chapter 16 Immunophenotypic Analysis of Acute Leukemia Chapter 17 Targeted Therapy for Leukemia Chapter 18 Thalidomide (Reaction Stop) for Malignant Hematological Diseases Appendix 1 Reference List of New and Old Drugs Appendix 2 English Abbreviations, Full Names and Chinese Comparison Table Appendix 3 Blood Cell Surface Markers and Antigen Cell Distribution